BlossomHill Therapeutics, Inc.
BLSMHealthcare|Biotechnology|US
$13.50
+1.15 (+9.31%)
DCF Value
$3.85
Tangible Book / Share
$3.02
Cash / Share
$3.51
Clinical Trials (2)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06706076 A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | NSCLC (Advanced Non-small Cell Lung Cancer) | P1P2 | Recruiting | 675 | Open-label | BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed, BH-30643 |
| NCT06501196 A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Leukemia, Leukemia, Myeloid | P1 | Recruiting | 170 | Open-label | BH-30236, Venetoclax |